ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes

What is it about?

The ADA/EASD Precision Medicine in Diabetes Initiative (PMDI) was launched in 2018 by the American Diabetes Association (ADA), in collaboration with the European Association for the Study of Diabetes (EASD). The PMDI has subsequently partnered with other organizations including the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), the Juvenile Diabetes Research Foundation (JDRF) and the Diabetes Technology Society (DTS). The mandate of the PMDI is to establish consensus on the viability and ultimate clinical implementation of precision medicine for the diagnosis, prevention, treatment, prognosis, and monitoring of diabetes. This process is designed to take place through systematic evaluation of available scientific evidence, expert consultation, and broad stakeholder engagement. The mandate of the PMDI is pursued with the overarching goal of facilitating longer, healthier lives for people living with diabetes, identifying those at risk, and preventing diabetes through multiple interventional approaches.

Featured Image